Targeting the CD161–CLEC2D pathway emerges as a promising therapeutic strategy to mitigate immunosuppression and enhance the efficiency of immunotherapy against MM (Figure 8). The gene discussed is CLEC2D; the disease is Miyoshi myopathy.